Johnson & Johnson stock at EUR 252.30, up 1.14% premarket
Published on 11/10/2026 at 08:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Progress Remains In Focus
- Johnson & Johnson's latest clinical update centers on an investigational prostate-cancer immunotherapy combination.
- The program is advancing toward Phase 3 after early PSA response results.
- The company operates across medicines, medical devices and consumer health.
Johnson & Johnson said on November 9 that an investigational combination of pasritamig and JNJ-9401 produced at least a 50% reduction in prostate-specific antigen in 73% of 15 patients in a Phase 1 study. The company said the dual-antibody program is advancing toward Phase 3 testing. The results were presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, according to the Johnson & Johnson release.
Premarket Trading Points Higher
Johnson & Johnson stock traded at 252.30 euros on Lang & Schwarz at 08:08 CET on Tuesday, November 10, 2026, 1.14 percent above the Xetra close of Monday, November 9, 2026.
The early-stage study adds another development milestone to the company's pharmaceutical pipeline, while the Phase 3 path creates a future catalyst but does not establish a commercial outcome.
Johnson & Johnson operates across medicines, medical devices and consumer health, giving investors exposure to several healthcare businesses rather than a single drug program.
Against the broader market backdrop, investors will also watch the S&P 500.
